Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.54 |
| ▸ | USP2 | O75604 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.48 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | F11 | P03951 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.46 |
| ▸ | PDE5A | O76074 | 1/20 | 0.46 |
| ▸ | HMGCR | P04035 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9850189 | 1.00 | PTPN1 (0.54) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL19263962 | 1.00 | PTPN1 (0.54) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL4300188 | 1.00 | PTPN1 (0.54) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL12595098 | 1.00 | PTPN1 (0.54) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL13396034 | 1.00 | PTPN1 (0.54) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL12140889 | 1.00 | PTPN1 (0.54) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL4300564 | 1.00 | PTPN1 (0.54) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL4785477 | 1.00 | PTPN1 (0.54) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL15959273 | 1.00 | PTPN1 (0.54) | PTPN1USP2POLBMEN1KMT2A | |
| SCHEMBL18256380 | 1.00 | PTPN1 (0.54) | PTPN1USP2POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | ROME THERAPEUTICS INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230138433-A1 | DEVELOPMENT OF NOVEL CLOFARABINE ANALOGS FOR CANCER THERAPY | SOUTHERN RESEARCH INSTITUTE | 2023-05-04 | — | — | US | disclosed |
| US-20230027361-A1 | METTL3 MODULATORS | ACCENT THERAPEUTICS, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| EP-4048674-A2 | METTL3 MODULATORS | Accent Therapeutics, Inc. (US) | 2022-08-31 | — | — | EP | disclosed |
| WO-2021079196-A9 | METTL3 MODULATORS | ACCENT THERAPEUTICS, INC (US) | 2022-07-14 | — | — | WO | disclosed |
| US-11254662-B2 | 2′-halogenated-4′-thio-2′-deoxy-5-azacytidine analogs and use thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-02-22 | — | — | US | disclosed |
| US-20220033387-A1 | 2'-HALOGENATED-4'-THIO-2'-DEOXY-5-AZACYTIDINE ANALOGS AND USE THEREOF | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-02-03 | — | — | US | disclosed |
| US-20210292310-A1 | 2'-HALOGENATED-4'-THIO-2'-DEOXY-5-AZACYTIDINE ANALOGS AND USE THEREOF | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-09-23 | — | — | US | disclosed |
| US-9187514-B2 | — | — | 2015-11-17 | — | — | US | disclosed |
| EP-2883866-A1 | INTERMEDIATE FOR SYNTHESIS OF 1-(2-DEOXY-2-FLUORO-4-THIO-beta-D-ARABINOFURANOSYL) CYTOSINE, INTERMEDIATE FOR SYNTHESIS OF THIONUCLEOSIDE, AND METHODS FOR PRODUCING THESE INTERMEDIATES | FUJIFILM Corporation (JP) | 2015-06-17 | — | — | EP | disclosed |
| US-20150152131-A1 | SYNTHETIC INTERMEDIATE OF 1-(2-DEOXY-2-FLUORO-4-THIO-ß-D-ARABINOFURANOSYL)CYTOSINE, SYNTHETIC INTERMEDIATE OF THIONUCLEOSIDE, AND METHOD FOR PRODUCING THE SAME | FUJIFILM CORPORATION (JP) | 2015-06-04 | — | — | US | disclosed |
| US-8835615-B2 | 2′-fluorine-4′-substituted-nucleoside analogues, preparation methods and uses thereof | HENAN GENUINE BIOTECH CO., LTD. (CN) | 2014-09-16 | — | — | US | disclosed |
| US-8835615-B2 | 2′-fluorine-4′-substituted-nucleoside analogues, preparation methods and uses thereof | HENAN GENUINE BIOTECH CO., LTD. (CN) | 2014-09-16 | — | — | US | disclosed |
| US-20100234584-A1 | 2'-Fluorine-4'-Substituted-Nucleoside Analogues, Preparation Methods and Uses Thereof | HENAN GENUINE BIOTECH CO., LTD. (CN) | 2010-09-16 | — | — | US | disclosed |
| US-20100234584-A1 | 2'-Fluorine-4'-Substituted-Nucleoside Analogues, Preparation Methods and Uses Thereof | HENAN GENUINE BIOTECH CO., LTD. (CN) | 2010-09-16 | — | — | US | disclosed |
| EP-2177527-A1 | 2'-FLUORO-4'-SUBSTITUTED NUCLEOSIDES, THE PREPARATION AND USE | Zhengzhou University (CN) | 2010-04-21 | — | — | EP | disclosed |
| US-7291726-B2 | Process for the preparation of 2′-halo-β-L-arabinofuranosyl nucleosides | BUKWANG PHARMACEUTICALS IND CO., LTD. (KR) | 2007-11-06 | — | — | US | disclosed |
| US-7291726-B2 | Process for the preparation of 2′-halo-β-L-arabinofuranosyl nucleosides | BUKWANG PHARMACEUTICALS IND CO., LTD. (KR) | 2007-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295212-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | PTPN1 2063/4885USP2 4681/4885POLB 16/4885 |
| US-20230374058-A1 | COMPOUNDS AND METHODS FOR TREATING DISEASE | EHMT1, POLRMT, RNASE1 | PTPN1 2063/4885USP2 4681/4885POLB 16/4885 |
| US-20230027361-A1 | METTL3 MODULATORS | METTL3, METTL16, METTL14 | PTPN1 3300/4885USP2 1640/4885POLB 2496/4885 |
| US-11254662-B2 | 2′-halogenated-4′-thio-2′-deoxy-5-azacytidine analogs and use thereof | DCTD, DPYD, TPMT | PTPN1 901/4885USP2 1939/4885POLB 418/4885 |
| US-20150152131-A1 | SYNTHETIC INTERMEDIATE OF 1-(2-DEOXY-2-FLUORO-4-THIO-ß-D-ARABINOFURANOSYL)CYTOSINE, SYNTHETIC INTERMEDIATE OF THIONUCLEOSIDE, AND METHOD FOR PRODUCING THE SAME | TYMS, TYMP, RRM2B | PTPN1 4171/4885USP2 4437/4885POLB 19/4885 |
| US-20220033387-A1 | 2'-HALOGENATED-4'-THIO-2'-DEOXY-5-AZACYTIDINE ANALOGS AND USE THEREOF | DCTD, DPYD, TPMT | PTPN1 934/4885USP2 1903/4885POLB 458/4885 |
| US-20230138433-A1 | DEVELOPMENT OF NOVEL CLOFARABINE ANALOGS FOR CANCER THERAPY | THPO, BRCA1, TYMS | PTPN1 2749/4885USP2 3019/4885POLB 1836/4885 |
| US-20210292310-A1 | 2'-HALOGENATED-4'-THIO-2'-DEOXY-5-AZACYTIDINE ANALOGS AND USE THEREOF | DCTD, DPYD, TPMT | PTPN1 934/4885USP2 1903/4885POLB 458/4885 |
| US-20100234584-A1 | 2'-Fluorine-4'-Substituted-Nucleoside Analogues, Preparation Methods and Uses Thereof | PNP, NUDT1, HNF4A | PTPN1 2551/4885USP2 4284/4885POLB 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.